Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib

被引：31
|
作者：
Kim, Gene H. [1 ,2 ]
Levy, Alan [3 ]
Compoginis, Goli [1 ,3 ]
机构：
[1] Univ So Calif, Dept Dermatol, Los Angeles, CA USA
[2] Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA
[3] Levy Dermatol, Memphis, TN USA
来源：
JOURNAL OF CUTANEOUS PATHOLOGY | 2013年 / 40卷 / 07期
关键词：
drug reaction; melanoma; panniculitis; vemurafenib; BRAF; GENETICS;
D O I：
10.1111/cup.12149
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Vemurafenib is an inhibitor of BRAF and is used to treat patients with metastatic melanoma who carry a V600E BRAF mutation. Recently, four patients have been described in the literature who developed a neutrophilic panniculitis following treatment with a BRAF inhibitor. We present an additional case and review the clinical findings of the cases reported to date.
引用
收藏
页码：667 / 669
页数：3
相关论文
共 50 条
  • [21] Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma
    Sanne EJ Wolf
    Christina Meenken
    Annette C Moll
    John B Haanen
    Michiel S van der Heijden
    BMC Cancer, 13
  • [22] Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma
    Boyd, Kevin P.
    Vincent, Bethaney
    Andea, Aleodor
    Conry, R. Martin
    Hughey, Lauren C.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 67 (06) : 1375 - 1379
  • [23] Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation
    Lheure, Coralie
    Kramkimel, Nora
    Franck, Nathalie
    Laurent-Roussel, Sara
    Carlotti, Agnes
    Queant, Astrid
    Goldwasser, Francois
    Avril, Marie-Francoise
    Dupin, Nicolas
    DERMATOLOGY, 2015, 231 (04) : 378 - 384
  • [24] Resistance to Vemurafenib Can Be Reversible After Treatment Interruption A Case Report of a Metastatic Melanoma Patient
    Mackiewicz-Wysocka, Malgorzata
    Krokowicz, Lukasz
    Kocur, Jacek
    Mackiewicz, Jacek
    MEDICINE, 2014, 93 (27)
  • [25] Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma
    Swaika, Abhisek
    Crozier, Jennifer A.
    Joseph, Richard W.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 775 - 787
  • [26] Metastatic melanoma and vemurafenib: novel approaches
    De Mello, Ramon Andrade
    RARE TUMORS, 2012, 4 (02) : 96 - 97
  • [27] Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma
    Grey, A.
    Cooper, A.
    McNeil, C.
    O'Toole, S.
    Thompson, J.
    Grimison, P.
    INTERNAL MEDICINE JOURNAL, 2014, 44 (06) : 597 - 600
  • [28] Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trial
    Grimaldi, Antonio M.
    Simeone, Ester
    Ascierto, Paolo A.
    MELANOMA MANAGEMENT, 2015, 2 (03) : 209 - 215
  • [29] BRAFV600 mutation levels predict response to vemurafenib in metastatic melanoma
    Lebbe, C.
    How-Kit, A.
    Battistella, M.
    Sadoux, A.
    Podgorniak, M. P.
    Sidina, I.
    Pages, C.
    Roux, J.
    Porcher, R.
    Tost, J.
    Mourah, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2014, 28 : 96 - 96
  • [30] BRAF inhibitor-induced panniculitis in patients treated for stage IV metastatic melanoma: a case series
    Bartlett, David J.
    Erie, Andrew J.
    Baffour, Francis I.
    Broski, Stephen M.
    Glazebrook, Katrina N.
    SKELETAL RADIOLOGY, 2021, 50 (06) : 1257 - 1262
12345